The sour side of neurodegenerative disorders: the effects of protein glycation
Identifieur interne : 000505 ( Main/Exploration ); précédent : 000504; suivant : 000506The sour side of neurodegenerative disorders: the effects of protein glycation
Auteurs : Hugo Vicente Miranda [Portugal] ; Tiago Fleming Outeiro [Portugal]Source :
- The Journal of Pathology [ 0022-3417 ] ; 2010-05.
English descriptors
- KwdEn :
Abstract
Neurodegenerative diseases are associated with the misfolding and deposition of specific proteins, either intra‐ or extracellularly in the nervous system. Although familial mutations play an important role in protein misfolding and aggregation, the majority of cases of neurodegenerative diseases are sporadic, suggesting that other factors must contribute to the onset and progression of these disorders. Post‐translational modifications are known to influence protein structure and function. Some of these modifications might affect proteins in detrimental ways and lead to their misfolding and accumulation. Reducing sugars play important roles in modifying proteins, forming advanced glycation end‐products (AGEs) in a non‐enzymatic process named glycation. Several proteins linked to neurodegenerative diseases, such as amyloid β, tau, prions and transthyretin, were found to be glycated in patients, and this is thought to be associated with increased protein stability through the formation of crosslinks that stabilize protein aggregates. Moreover, glycation may be responsible, via the receptor for AGE (RAGE), for an increase in oxidative stress and inflammation through the formation of reactive oxygen species and the induction of NF‐κB. Therefore, it is essential to unravel the molecular mechanisms underlying protein glycation to understand their role in neurodegeneration. Here, we reviewed the role of protein glycation in the major neurodegenerative disorders and highlight the potential value of protein glycation as a biomarker or target for therapeutic intervention. Copyright © 2009 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
Url:
DOI: 10.1002/path.2682
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">The sour side of neurodegenerative disorders: the effects of protein glycation</title><author><name sortKey="Miranda, Hugo Vicente" sort="Miranda, Hugo Vicente" uniqKey="Miranda H" first="Hugo Vicente" last="Miranda">Hugo Vicente Miranda</name></author><author><name sortKey="Outeiro, Tiago Fleming" sort="Outeiro, Tiago Fleming" uniqKey="Outeiro T" first="Tiago Fleming" last="Outeiro">Tiago Fleming Outeiro</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:5BA53E797F701671FA037095C73504DCD403F21F</idno><date when="2010" year="2010">2010</date><idno type="doi">10.1002/path.2682</idno><idno type="url">https://api.istex.fr/document/5BA53E797F701671FA037095C73504DCD403F21F/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">002D79</idno><idno type="wicri:Area/Main/Curation">002A01</idno><idno type="wicri:Area/Main/Exploration">000505</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">The sour side of neurodegenerative disorders: the effects of protein glycation</title><author><name sortKey="Miranda, Hugo Vicente" sort="Miranda, Hugo Vicente" uniqKey="Miranda H" first="Hugo Vicente" last="Miranda">Hugo Vicente Miranda</name><affiliation wicri:level="1"><country xml:lang="fr">Portugal</country><wicri:regionArea>Enzymology group, Departamento de Quimica e Bioquimica, Centro de Quimica e Bioquimica, Faculdade de Ciencias da Universidade de Lisboa, Campo grande, Edificio C8, 1749‐016, Lisboa</wicri:regionArea><wicri:noRegion>Lisboa</wicri:noRegion></affiliation><affiliation wicri:level="1"><country xml:lang="fr">Portugal</country><wicri:regionArea>Cell and Molecular Neuroscience Unit, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Av. Prof. Egas Moniz, 1649‐028 Lisboa</wicri:regionArea><wicri:noRegion>1649‐028 Lisboa</wicri:noRegion></affiliation></author><author><name sortKey="Outeiro, Tiago Fleming" sort="Outeiro, Tiago Fleming" uniqKey="Outeiro T" first="Tiago Fleming" last="Outeiro">Tiago Fleming Outeiro</name><affiliation wicri:level="1"><country xml:lang="fr">Portugal</country><wicri:regionArea>Cell and Molecular Neuroscience Unit, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Av. Prof. Egas Moniz, 1649‐028 Lisboa</wicri:regionArea><wicri:noRegion>1649‐028 Lisboa</wicri:noRegion></affiliation><affiliation wicri:level="1"><country xml:lang="fr">Portugal</country><wicri:regionArea>Instituto de Fisiologia, Faculdade de Medicina da Universidade de Lisboa, Av. Prof. Egas Moniz, 1649‐028 Lisboa</wicri:regionArea><wicri:noRegion>1649‐028 Lisboa</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">The Journal of Pathology</title><title level="j" type="abbrev">J. Pathol.</title><idno type="ISSN">0022-3417</idno><idno type="eISSN">1096-9896</idno><imprint><publisher>John Wiley & Sons, Ltd.</publisher><pubPlace>Chichester, UK</pubPlace><date type="published" when="2010-05">2010-05</date><biblScope unit="volume">221</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="13">13</biblScope><biblScope unit="page" to="25">25</biblScope></imprint><idno type="ISSN">0022-3417</idno></series><idno type="istex">5BA53E797F701671FA037095C73504DCD403F21F</idno><idno type="DOI">10.1002/path.2682</idno><idno type="ArticleID">PATH2682</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0022-3417</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>AGE</term><term>RAGE</term><term>amyloid β</term><term>glycation</term><term>neurodegeneration</term><term>post‐translational modification</term><term>prions</term><term>tau</term><term>transthyretin</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Neurodegenerative diseases are associated with the misfolding and deposition of specific proteins, either intra‐ or extracellularly in the nervous system. Although familial mutations play an important role in protein misfolding and aggregation, the majority of cases of neurodegenerative diseases are sporadic, suggesting that other factors must contribute to the onset and progression of these disorders. Post‐translational modifications are known to influence protein structure and function. Some of these modifications might affect proteins in detrimental ways and lead to their misfolding and accumulation. Reducing sugars play important roles in modifying proteins, forming advanced glycation end‐products (AGEs) in a non‐enzymatic process named glycation. Several proteins linked to neurodegenerative diseases, such as amyloid β, tau, prions and transthyretin, were found to be glycated in patients, and this is thought to be associated with increased protein stability through the formation of crosslinks that stabilize protein aggregates. Moreover, glycation may be responsible, via the receptor for AGE (RAGE), for an increase in oxidative stress and inflammation through the formation of reactive oxygen species and the induction of NF‐κB. Therefore, it is essential to unravel the molecular mechanisms underlying protein glycation to understand their role in neurodegeneration. Here, we reviewed the role of protein glycation in the major neurodegenerative disorders and highlight the potential value of protein glycation as a biomarker or target for therapeutic intervention. Copyright © 2009 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.</div></front></TEI><affiliations><list><country><li>Portugal</li></country></list><tree><country name="Portugal"><noRegion><name sortKey="Miranda, Hugo Vicente" sort="Miranda, Hugo Vicente" uniqKey="Miranda H" first="Hugo Vicente" last="Miranda">Hugo Vicente Miranda</name></noRegion><name sortKey="Miranda, Hugo Vicente" sort="Miranda, Hugo Vicente" uniqKey="Miranda H" first="Hugo Vicente" last="Miranda">Hugo Vicente Miranda</name><name sortKey="Outeiro, Tiago Fleming" sort="Outeiro, Tiago Fleming" uniqKey="Outeiro T" first="Tiago Fleming" last="Outeiro">Tiago Fleming Outeiro</name><name sortKey="Outeiro, Tiago Fleming" sort="Outeiro, Tiago Fleming" uniqKey="Outeiro T" first="Tiago Fleming" last="Outeiro">Tiago Fleming Outeiro</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000505 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000505 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:5BA53E797F701671FA037095C73504DCD403F21F
|texte= The sour side of neurodegenerative disorders: the effects of protein glycation
}}
| This area was generated with Dilib version V0.6.23. |  |